Results 11 to 20 of about 30,614,581 (155)

An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist [PDF]

open access: yesNew England Journal of Medicine, 2009
Autoinflammatory diseases manifest inflammation without evidence of infection, high-titer autoantibodies, or autoreactive T cells. We report a disorder caused by mutations of IL1RN, which encodes the interleukin-1-receptor antagonist, with prominent involvement of skin and bone.We studied nine children from six families who had neonatal onset of ...
Aksentijevich, I   +41 more
core   +6 more sources

Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist : a Mendelian randomisation analysis [PDF]

open access: yes, 2015
Funded by: UK Medical Research Council, British Heart Foundation, UK National Institute for Health Research, National Institute for Health Research Cambridge Biomedical Research Centre, European Research Council, and European Commission Framework ...
D. F. Easton (7608179)   +874 more
core   +5 more sources

Interleukin-1 receptor antagonist: a promising cytokine against human squamous cell carcinomas

open access: yesHeliyon, 2023
Inflammation, especially chronic inflammation, is closely linked to tumor development. As essential chronic inflammatory cytokines, the interleukin family plays a key role in inflammatory infections and malignancies.
Yujie Ding   +3 more
doaj   +1 more source

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies [PDF]

open access: yes, 2012
BACKGROUND: Persistent inflammation has been proposed to contribute to various stages in the pathogenesis of cardiovascular disease. Interleukin-6 receptor (IL6R) signalling propagates downstream inflammation cascades.
Thomas, GN   +492 more
core   +1 more source

Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding [PDF]

open access: yes, 2009
Background: Atherosclerosis is an inflammatory process that develops in individuals with known risk factors that include hypertension and hyperlipidaemia, influenced by diet.
Dower, S.   +25 more
core   +1 more source

Association between IL-1A, IL-1B and IL-1RN Polymorphisms and Peri-Implantitis: A Systematic Review and Meta-Analysis

open access: yesApplied Sciences, 2022
Recent studies report that individuals with polymorphisms in the genes that encode for interleukin (IL)-1α and IL-1β (IL-1A and IL1B, respectively) and for IL-1 receptor antagonist (IL-1RN) may be more susceptible in developing peri-implantitis ...
José Maria Cardoso   +5 more
doaj   +1 more source

The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes:the MRC-ILA Heart Study [PDF]

open access: yes, 2014
AIMS: Acute coronary syndromes (ACSs) are driven by inflammation within coronary plaque. Interleukin-1 (IL-1) has an established role in atherogenesis and the vessel-response to injury. ACS patients have raised serum markers of inflammation.
Greenwood, J.P.   +29 more
core   +1 more source

Evaluation of the Interleukin-1 Receptor Antagonist and Immunoregulatory Interleukin-10 in the Middle Ear in Chronic Otitis Media With Effusion in Children With and Without Atopy [PDF]

open access: yesClinical and Experimental Otorhinolaryngology, 2016
Objectives The role of pro-inflammatory cytokines in the course of chronic otitis media with effusion (COME) has been documented. However, there are fewer studies on the action of anti-inflammatory cytokines in the middle ear. We sought determine whether
Beata Zielnik-Jurkiewicz   +1 more
doaj   +1 more source

Truncated Chicken Interleukin-1β with Increased Biologic Activity [PDF]

open access: yes, 2003
Chicken interleukin-1β (ChIL-1β) is synthesized as a precursor molecule that unlike its mammalian counterpart, lacks a typical caspase-1 cleavage site. Therefore, it was unclear if proteolytic cleavage of ChIL-1β can occur and if cleavage might modulate ...
Erno Duda   +10 more
core   +1 more source

Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1α antibody, in a phase III randomized study of advanced colorectal cancer

open access: yesOncoImmunology, 2019
Bermekimab is a true human monoclonal antibody that targets interleukin-1alpa (IL-1α), an inflammation-mediating alarmin. IL-1 receptor antagonist (IL-1Ra) is a natural molecule that blocks IL-1α activity by occupying the IL-1 receptor.
Razelle Kurzrock   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy